RESUMEN
Objective:To explore the clinical effect of compound glycyrrhizin tablets combined with recombinant bovine basic fibroblast growth factor gel in the treatment of facial hormone-dependent dermatitis. Methods:Totally 108 patients with facial hormone-dependent dermatitis were selected randomly and divided into the control group(n = 54) and the treatment group(n =54). The control group was treated with desloratadine and 0.1% tacrolimus ointment;and the treatment group was treated with compound glycyrrhizin tablets combined with recombinant bovine basic fibroblast growth factor gel additionally on the basis of control group. The clinical efficacy of the two groups was evaluated,and the improvement of symptoms and objective signs before and after the treatment was compared. The adverse reactions were recorded as well. Results:The total effective rate of the treatment group after one-month and two-month treatment was 75.93% and 90.74%, respectively, which were both higher than those of the control group(P < 0.05). The scores of symptoms and objective signs and the total scores of disease of the treatment group after one-month and two-month treatment and two-month follow-up were all lower than those of the control group, and the differences were statistically significant(P <0.05). The disappearance time of objective signs and the incidence of facial adverse reactions were both lower than those of the control group,and the differences were statistically significant(P < 0.05),however, the incidence of dry mouth in the treatment group was higher than that in the control group(P < 0.05). Conclusion:Compound glycyrrhizin tablets combined with recombinant bovine basic fibroblast growth factor gel has better clinical effect for the therapy of facial hormone-dependent dermatitis,which can improve the symptoms significantly with high application security.
RESUMEN
Objective To investigate the clinical efficacy and safety of triclosan in combination with compound glycyrrhizin in the treatment of chronic urticaria. Methods A total of 100 patients with chronic urticaria who were enrolled in our hospital from December 2014 to December 2015 were divided into control group and observation group by random number table method,with 50 cases in each group. The control group was given desloratadine alone, and the observation group was treated with on the basis of the addition of compound glycyrrhizin tablets adjuvant therapy.compare the two groups of patients withThe short-term efficacy,the scores of 7 days urticaria activity,the laboratory indicators and the rate of follow-up recurrence were compared before and after treatment in two groups. Results The total effective rate (96.00％) of the observation group was significantly higher than that of the control group (76.00％) (P <0.05). After the treatment of 7days, the urticaria and itching score in the observation group [(0.79 ± 0.20), (0.65 ± 0.10)] were significantly lower than the control group [(1.54 ± 0.29), (1.29 ± 0.42)] (P<0.05). The levels of IL-4, IFN-γ and IgE in the observation group [(28.16 ± 4.10) pg / mL, (11.95 ± 3.05) pg / mL, (55.21 ± 11.37 g / L) were significantly higher than those in the control group[(35.40 ± 7.92) pg/mL,(7.23 ± 1.89) pg/mL, (73.75 ± 15.09) g/L] (P<0.05). The recurrence rate (10.00％, 18.00％) in the observation group was significantly lower than that in the control group (24.00％, 36.00％) (P<0.05).Conclusion The treatment of chronic urticaria with cisplatin combined with compound glycyrrhizin can alleviate the symptoms of skin lesions, improve the level of related laboratory indicators and help to avoid long-term recurrence.